<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033522</url>
  </required_header>
  <id_info>
    <org_study_id>MBI-003-LIVE</org_study_id>
    <nct_id>NCT05033522</nct_id>
  </id_info>
  <brief_title>Immunotherapy for Advanced Liver Cancer</brief_title>
  <acronym>ALIVE</acronym>
  <official_title>Phase II/III Randomized, Controlled Clinical Study of AlloStim(R) vs Physician's Choice in Asian Subjects With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovative Therapies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mirror Biologics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunovative Therapies, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled multi-site, multi-national clinical trial conducted in&#xD;
      Thailand and Malaysia for naïve Asian adults (males or females), 18 years of age and older&#xD;
      presenting with advanced HCC (BCLC stage C) including subjects with vascular involvement&#xD;
      and/or extrahepatic spread (not eligible for TACE, surgery or locoregional treatment) with&#xD;
      Child-Pugh stage A or B liver function and either unable to assess, or not eligible for,&#xD;
      sorafenib first line treatment. 180 subjects will be randomized 2:1 to AlloStim®&#xD;
      immunotherapy vs Physician's Choice of Best Supportive Care or FOLFOX4 chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-national, randomized, controlled trial (RCT) with multiple sites selected in Asia&#xD;
      (Malaysia and Thailand). Subjects with no prior treatments presenting with BCLC stage C&#xD;
      disease and Child-Pugh class A or B liver reserve without access to sorafenib to be&#xD;
      randomized 2:1 to AlloStim® vs. Physician's Choice (PC). PC to be declared prior to&#xD;
      randomization. PC allowed to be either best supportive care (BSC) or best supportive care&#xD;
      with palliative chemotherapy (FOLFOX4). Prior or planned treatment with active systemic&#xD;
      therapies (e.g., levantinib, nivolumab, duvalumab, tremelimumab, brivananib, cabozantinib and&#xD;
      ramucircumab) or procedures (e.g., TACE, RFA, ETOH ablation, surgery, radiation) excluded.&#xD;
&#xD;
      The world incidence of hepatocellular carcinoma (HCC) is highest in East and South East Asia,&#xD;
      with nearly half of the all HCC cases and deaths globally occurring in China. In Asian&#xD;
      countries, the main treatment options for early or intermediate HCC (BCLC class A and B)&#xD;
      include surgical resection, ablation (e.g., RFA, ETOH, cryoablation), transarterial&#xD;
      chemoembolization (TACE), radiation or systemic chemotherapy depending on liver function&#xD;
      status. However, in the Asian-Pacific region it is estimated that up to 80% of patients&#xD;
      present with unresectable, advanced HCC (BCLC Stage C) that are not eligible for locoregional&#xD;
      therapy, surgery or TACE due to tumor size and/or vascular involvement. For these patients,&#xD;
      the standard of care for over a decade has been sorafenib (Bayer, A.G.), a oral kinase&#xD;
      inhibitor based on the results of a RCT (SHARP study) of 602 patients randomized to sorafenib&#xD;
      vs. placebo. Median overall survival (OS) was 10.7 months for sorafenib and 7.9 months for&#xD;
      placebo (p&lt;0.05). The SHARP study included a Western population. A separate study in Asian&#xD;
      patients (226 patients from China, South Korea and Taiwan) comparing sorafenib to placebo&#xD;
      (Sorafenib-AP study) demonstrated a OS of 6.5 months for sorafenib compared to 4.2 months for&#xD;
      placebo (p&lt;0.05). The placebo OS difference between Asian and Western patients (4.2mo vs 7.9&#xD;
      mo) suggests a difference in the disease characteristics in the Asian population. One&#xD;
      significant difference is that the Asian population has an increased prevalence of HBV&#xD;
      compared to Western population which may contribute to the increased incidence of HCC and&#xD;
      worse OS outcomes observed in Asian patients compared to Western patients.&#xD;
&#xD;
      In Thailand and Malaysia sorafenib is not available to a majority of the population&#xD;
      presenting with advanced HCC, both due to cost and toxicity profile. This study is designed&#xD;
      to evaluate whether AlloStim ® immunotherapy will provide a survival benefit to this&#xD;
      population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects are randomized 2:1 to experimental vs physician's choice. A two-sided logrank test with an overall sample size of 130 subjects (43 in the control group and 87 in the treatment group) achieves 80% power to detect at a 0.05 significance level a hazard ratio of 0.56 when the control group median survival is 4.2 months. A total of 150 subjects are planned to be accrued.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The investigator and subjects will be informed of the treatment group to which the subject has been randomized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>rom date of randomization until the date of death from any cause, assessed up to 48 months</time_frame>
    <description>the time from randomization till death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey</measure>
    <time_frame>weekly assessments from baseline to 28 weeks</time_frame>
    <description>using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire (FACT-Hep)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptomatic Progression</measure>
    <time_frame>rom date of randomization weekly for up to 24 weeks until the date of first documented progression which ever comes first</time_frame>
    <description>To assess time to symptomatic progression (TTSP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>AlloStim®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AlloStim® is a formulation of living allogeneic Th1-like cells with anti-CD3/CD28 microbeads attached derived from precursors purified from healthy screened blood donors that are differentiated and expanded ex-vivo. AlloStim® is formulated at 10-7 cells/ml in 0.5ml for ID administration and 3ml for IV administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physician's Choice is either palliative FOLFOX4 chemotherapy plus best supportive care or best supportive care alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim® immunotherapy</intervention_name>
    <description>3 cycles of intradermal and intravenous administrations</description>
    <arm_group_label>AlloStim®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>Comparative arm: Physician Choice of palliative chemotherapy+best supportive care or best supportive care alone</description>
    <arm_group_label>Physician's Choice</arm_group_label>
    <other_name>Physician Choice FOLFOX4+Best Supportive Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Comparative arm: Physician Choice of palliative chemotherapy+best supportive care or best supportive care alone</description>
    <arm_group_label>Physician's Choice</arm_group_label>
    <other_name>Physician Choice Best Supportive Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females who are at least 18 years of age at time of enrollment&#xD;
&#xD;
          2. Histologically or cytologically documented advanced HCC (BCLC stage C) disease at&#xD;
             diagnosis.&#xD;
&#xD;
          3. No prior HCC treatment. (exclude if prior local therapy, such as surgery, radiation,&#xD;
             TACE, RFA, ETOH ablation, cryoablation)&#xD;
&#xD;
          4. Child-Pugh Class A and not able to assess sorafenib or Child-Pugh Class B and not&#xD;
             eligible for sorafenib&#xD;
&#xD;
          5. Performance status: ECOG &lt; 2 with no deterioration over the previous 2 weeks&#xD;
&#xD;
          6. With or without positive HBV and/or HCV&#xD;
&#xD;
          7. With or without extrahepatic disease and with or without macrovascular invasion&#xD;
&#xD;
          8. Measurable enhancing disease in liver with at least one target lesion evaluable by&#xD;
             mRECIST&#xD;
&#xD;
          9. Adequate hematological, liver and renal function as assessed by the following:&#xD;
&#xD;
               -  Hemoglobin &gt; 10.0 g/dl&#xD;
&#xD;
               -  Platelet count &gt; 75,000/μl&#xD;
&#xD;
               -  ALT and AST &lt; 5.0 x ULN&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5&#xD;
&#xD;
         10. Women of child-bearing potential: negative pregnancy test&#xD;
&#xD;
         11. Patients of child producing potential: usage of contraception or avoidance of&#xD;
             pregnancy measures while enrolled on study&#xD;
&#xD;
         12. Ability to understand the study, its inherent risks, side effects and potential&#xD;
             benefits and ability to give written informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior cancer diagnosis (other than cured basal cell carcinoma, head and neck&#xD;
             carcinoma in-situ, or superficial Ta, Tis, T1 bladder cancer) or concurrent cancer&#xD;
             histologically different than HCC (e.g., cholangiocarcinoma).&#xD;
&#xD;
          2. Child-Pugh liver function combined score &gt;9 (Class C or Class D)&#xD;
&#xD;
          3. Moderate uncontrolled or severe ascites (+3 on Child-Pugh calculator)&#xD;
&#xD;
          4. Clinical symptoms of hepatic decompensation or presence of hepatic encephalopathy&#xD;
&#xD;
          5. Severe stomach/esophageal varices requiring interventional treatment.&#xD;
&#xD;
          6. Unable to tolerate radiological contrast dye&#xD;
&#xD;
          7. Any prior experimental, approved or off-label treatment for HCC (including levantinib,&#xD;
             nivolumab, duvalumab, tremelimumab, brivananib, cabozantinib or ramucircumab) or any&#xD;
             approved or experimental procedures such as surgery, radiation or ablation.&#xD;
&#xD;
          8. Enrollment in any previous clinical trial for HCC&#xD;
&#xD;
          9. Any history of autoimmune disorder (type I, insulin-dependent diabetes allowed)&#xD;
&#xD;
         10. History of COPD or oxygen saturation &lt;92% at room air&#xD;
&#xD;
         11. Any clinical condition requiring systemic steroids (inhaled steroids allowed) or any&#xD;
             current immunosuppressive therapy or anti-epileptic drug therapy.&#xD;
&#xD;
         12. Known history of HIV infection&#xD;
&#xD;
         13. Clinically significant gastrointestinal bleeding within 30 days prior to study entry&#xD;
&#xD;
         14. History of cardiac disease: congestive heart failure &gt; NYHA class 2; cardiac&#xD;
             arrhythmias requiring anti-arrhythmic therapy (beta blockers or Digoxin are permitted)&#xD;
&#xD;
         15. Uncontrolled hypertension (SBP &gt;150 or DBP&gt;90).&#xD;
&#xD;
         16. Active clinically serious infections (&gt; grade 2 CTCAE version 5.0)&#xD;
&#xD;
         17. History of organ transplant or tissue allograft&#xD;
&#xD;
         18. Uncontrolled concurrent serious medical or psychiatric illness&#xD;
&#xD;
         19. Clinically apparent central nervous system metastases or carcinomatous meningitis&#xD;
&#xD;
         20. History of drug abuse or current alcohol abuse&#xD;
&#xD;
         21. History of blood transfusion reactions&#xD;
&#xD;
         22. Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe Tournerie, MD</last_name>
    <phone>+65 64365501</phone>
    <email>ctournerie@clinactis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon NG, RN</last_name>
    <phone>+65 64365502</phone>
    <email>sng@clinactis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Pulau Pinang</city>
        <state>George Town</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Farah Amalina Binti Mohamed Affandi, RN</last_name>
      <phone>+60 13-3688292</phone>
      <email>farah.amalina@clinicalresearch.my</email>
    </contact>
    <investigator>
      <last_name>Heng Chin Fong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sultan Ismail Hospital</name>
      <address>
        <city>Johor Bahru</city>
        <state>Johor</state>
        <zip>81100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Siti Zurairah binti Md Saif, RN</last_name>
      <phone>+60 7-3565000</phone>
      <phone_ext>5155</phone_ext>
      <email>zurairah@clinicalresearch.my</email>
    </contact>
    <investigator>
      <last_name>Sen Chun Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sultanah Bahiyah Hospital</name>
      <address>
        <city>Alor Setar</city>
        <state>Kedah</state>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Ms Kamila, RN</last_name>
      <phone>+60 12-5630335</phone>
      <email>kamila@clinicalresearch.my</email>
    </contact>
    <investigator>
      <last_name>Datuk Dr Muhammad Radzi Abu Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nilai Medical Center</name>
      <address>
        <city>Bandar Permaisuri</city>
        <state>Negeri Sembilan</state>
        <zip>71800</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Tamil Selvi, RN</last_name>
      <phone>+60 12-506389</phone>
      <email>selvi@nilaimc.com</email>
    </contact>
    <investigator>
      <last_name>Kananathan Ratnavelu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chandrashekar Hospet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Saranya Sarapat (คุณปุ้ย), RN</last_name>
      <phone>+66 2-419-2976</phone>
      <email>arunya_s@windowslive.com</email>
    </contact>
    <investigator>
      <last_name>Krittiya Korphaisarn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Nopparat Natekaew (น้องนุ๊ก), RN</last_name>
      <phone>+66 2 201 1666</phone>
      <email>nookelfsuju05@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Abhasnee Sobhonslidsuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Songkla University (Songklanagarind Hospital)</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <phone>+66 74 451 469</phone>
      <email>dr.arunee@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Keson Trakunram, RN</last_name>
      <phone>+66 74 451 469</phone>
      <email>puykeson.t@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Arunee Dechaphunkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naresuan University Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <state>Tha Pho</state>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Prathana Anekpunyakul, RN</last_name>
      <phone>+66 5596 7903</phone>
      <email>prathanaa@nu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Ekawee Sripariwuth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.mirrorbio.com</url>
    <description>sponsor website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>Thailand</keyword>
  <keyword>Malaysia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

